Diabetes Obes Metab: Removing chronic hepatitis C virus infection can reduce the incidence of type 2 diabetes.

HCV infection increases the risk of type 2 diabetes (T2DM).
, however, it is not clear whether the removal of HCV through direct-acting antiviral drugs (DAA) will reduce the T2DM rate.
recently, a study published in Thebetes Obesity and Metabolism, a authoritative journal in the field of metabolic endocrine diseases, assessed the impact of HCV eradication on T2DM incidence.
researchers conducted a prospective multi-center case-control study that included 2,426 HCV patients, 42 percent of whom had F0-F2 liver fibrosis and 58 percent had F3-F4 liver fibrosis.
study also included 1,099 untreated patients and 1,327 patients treated with DAA as control groups.
the T2DM rate was assessed during the follow-up period with a median of 30 months .IQR:28-42.
the researchers assessed the risk factors for T2DM using The Cox Regression Model (Relative Risk (RR), Risk Ratio (HR), Kaplan-Meier, and the insulin sensitivity was assessed through HOMA, and the changes were repeatedly measured using ANOVA.
researchers evaluated factors associated with T2DM independence through multi-factor analysis.
incidence of T2DM in the control group and the case group was 28 and 7 per year, respectively, for 1,000 people (p-0.001).
, HCV removal reduced T2DM's RR and HR by 81% and 75-93%, respectively, compared to the control group.
calculated that one T2DM patient could be saved for every 15 patients who cleared HCV.
HCV removal was associated with significant reductions in HOMA-IR and HOMA-beta assessment and HOMA-S elevation in 384 patients before and after HCV removal.
in multivariable analysis, HCV removal is independently related to reduced T2DM risk.
thus, the removal of HCV through DAA therapy can reduce the rate of T2DM, possibly by restoring the HCV-induced glucose steady state mechanism.
.